Skip to main content
$248.27 $2.78 (1.1%)

04:00 PM EST on 01/19/21

Amgen, Inc. (NASDAQ:AMGN)

CAPS Rating: 4 out of 5

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Current Price $248.27 Mkt Cap $0.00
Open $246.50 P/E Ratio 0.00
Prev. Close $248.27 Div. (Yield) $0.00 (0.0%)
Daily Range $246.38 - $249.00 Volume 2,172,907
52-Wk Range $246.38 - $249.00 Avg. Daily Vol.

Caps

How do you think NASDAQ:AMGN will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,185 Outperform
169 Underperform
 

All-Star Players

483 Outperform
22 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:AMGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

hennyfamily (51.09)
Submitted March 07, 2019

Terrific company and has a game changing migraine drug in early monetization stage. Trading near December lows now and is too darn cheap

bclan13 (43.41)
Submitted February 05, 2013

I don't see anything replacing the big supportive care indications, which will probably get cut in half in coming years by a combination of biosimilars and increasing price sensitivity by numerous governments. This said,, it's a hard call for me be… More

Recent Community Commentary

Read the most recent pitches from players about AMGN.

Recs

0
Member Avatar TMFjbonefish (52.34) Submitted: 1/12/2021 7:20:54 PM : Outperform Start Price: $237.12 NASDAQ:AMGN Score: +4.71

Stable of products can withstand generics while they keep paying a rising dividend.

Recs

0
Member Avatar TMFjimhalley (67.67) Submitted: 1/10/2021 10:37:10 PM : Outperform Start Price: $235.53 NASDAQ:AMGN Score: +5.20

I expect the company's revenue to continue to climb in 2021 and at the stock's current price-to-earnings ratio, it appears to have plenty of room to go higher.

Recs

0
Member Avatar TMFacarchidi (65.88) Submitted: 10/7/2020 12:23:58 PM : Outperform Start Price: $256.03 NASDAQ:AMGN Score: -14.59

Massive expansion of its biosimilar portfolio, which offers the chance to produce generics of highly effective biologics that other companies had to spend developing. Furthermore, the company's leadership has shown tremendous flexibility in catering its drug pricing to what markets can support, thereby capturing a larger share in the process.

Leaderboard

Find the members with the highest scoring picks in AMGN.

Score Leader

Gardere

Gardere (< 20) Score: +485.76

The Score Leader is the player with the highest score across all their picks in AMGN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Gardere < 20 3/20/2008 Outperform NS $31.59 +686.00% +200.24% +485.76 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. golfdynamo 49.39 3/24/2008 Outperform NS $31.90 +678.16% +194.55% +483.60 0 Comment
bappy29 < 20 3/24/2008 Outperform 3W $31.90 +678.16% +194.55% +483.60 1 Comment
gokulesh < 20 3/24/2008 Outperform 3Y $31.90 +678.16% +194.55% +483.60 0 Comment
RyWoods 58.70 3/24/2008 Outperform 3Y $31.90 +678.16% +194.55% +483.60 0 Comment
dhcrosse 81.25 3/24/2008 Outperform 1Y $31.90 +678.16% +194.55% +483.60 0 Comment
KarenSmart < 20 3/24/2008 Outperform NS $31.90 +678.16% +194.55% +483.60 0 Comment
jchrismc < 20 3/24/2008 Outperform 1Y $31.90 +678.16% +194.55% +483.60 0 Comment
GFunkmeister < 20 3/26/2008 Outperform 3W $32.36 +667.22% +192.04% +475.18 0 Comment
kerrdog65 34.05 3/26/2008 Outperform 1Y $32.36 +667.22% +192.04% +475.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AMGN.